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Purpose: This study was undertaken with the objective of evaluating the biopharmaceutical equivalency 
of ten brands of ciprofloxacin tablets and the chemical equivalency with the use of an analytical method, 
which will be easy to use, accurate, reproducible, simple, and inexpensive.  
Method: The biopharmaceutical and chemical equivalence of ten brands of ciprofloxacin hydrochloride 
tablets were assessed through the evaluation of the uniformity of weight, friability test, hardness, 
disintegration test, dissolution rate, thin layer chromatography and non-aqueous titration procedure with 
the use of crystal violet solution indicator. 
Result: All the brands complied with the official specification for uniformity of weight and friability test, 
while one of the brands failed the disintegration test. The dissolution rate profile revealed that four of the 
brands did not attain 70% dissolution throughout the period of the determination, while the other brands 
had above 70% dissolution at less than 45minutes. The non-aqueous titrimetric procedure showed that 
the excipients did not affect the procedure; with seven brands having values within the range specified 
in the USP, while the remaining three brands gave lower values.  
Conclusion: Six of the brands evaluated in this study could be regarded as being biopharmaceutically 
and chemically equivalent, while a particular brand is obviously a fake product. The non-aqueous 
titrimetric procedure used in this study is simple, inexpensive, and easy to use and could be used in 
routine monitoring of the quality of ciprofloxacin HCl tablets, especially in the absence of high 
technology equipments that are not easily available in most developing countries.  
 
 





*Corresponding Author:  email: duplag03@yahoo.com. 
Adegbolagun et al  
Trop J Pharm Res, September 2007; 6 (3) 738 
INTRODUCTION 
The introduction of generic drug product from 
multiple sources into the health care delivery 
system of many developing countries was aimed 
at improving the overall healthcare delivery 
systems in such countries. However, this has 
been accompanied by a variety of problems of 
which the most critical is the widespread 
distribution of fake and substandard drug 
products.  
 
The need to select one product from among 
several generic drug products of the same active 
ingredients during the course of therapy is a 
cause of concern to a healthcare practitioner. 
The first stage in ascertaining the therapeutic 
equivalence of any drug product involves 
ascertaining the chemical and biopharmaceutical 




Drug products that are chemically and 
biopharmaceutically equivalent must be identical 
in strength, quality, purity as well as content 
uniformity, disintegration and dissolution rates
2
. 
The need to ensure that the generic and 
branded drug products are pharmaceutically and 
therapeutically equivalent cannot be over 
emphasized. Variable clinical response to the 
same dosage form of a drug product supplied by 
different manufacturers has been reported
3,4
; 
therapeutic inequivalences have been reported 
from the use of some generic brands of drug 




In Nigeria, chemical and biopharmaceutical 








 capsules. However, in a study on 
eight brands of sulphadoxine-pryrimethamine 
tablets, chemical as well as biopharmaceutical 
equivalency was observed with three out of eight 
brands tested, while the remaining five brands 




There are several brands of ciprofloxacin 
hydrochloride tablets available within the drug 
delivery system globally as well as in Nigeria. 
The increasing level of use of ciprofloxacin 
hydrochloride tablets as a result of its versatility 
in the management of various cases of 
microbiological infections
10
 necessitated the 
need to evaluate the quality of the various 
brands available.  
 
Ascertaining the quality of drug products 
involves the use of various procedures which 
includes both biopharmaceutical and chemical 
assay techniques. Various methods have been 
reported for the chemical assay of ciprofloxacin 
tablets. The United State Pharmacopoeia 
(USP)
11
 and British Pharmacopoiea (BP)
12
 
recommend liquid chromatographic methods for 
the tablets, while non-aqueous titrimetry with 
potentiometric determination of end point is used 
for the pure drug compound. 
 
Others workers have reported methods ranging 
from derivatization coupled with ion-pair 
complexation reaction, capillary electrophoresis, 
high performance liquid chromatography 
(HPLC), colorimetry to spectrophotometric 
technique
13,14,15
. However, all these methods 
usually require the use of sophisticated 
equipment coupled with high cost of analysis. 
Thus, most developing countries are not able to 
use the methods. 
 
Although, the World Health Organization (WHO) 
issued guidelines for global standardization and 
requirements for the registration, assessment, 
marketing, authorization and quality control of 
generic drug products
16
, many developing 
countries do not have the technical, financial, or 
human resources required to monitor the quality 





The objective of this study was to evaluate the 
biopharmaceutical equivalency of ten brands of 
ciprofloxacin tablets as well as their chemical 
equivalency through the use of an analytical 
method, which will be easy to use, simple, and 
inexpensive with results, which compare 
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EXPERIMENTAL  
Materials 
 Ciprofloxacin HCl pure powder was a gift from 
Gemini Pharmaceutical Industry, Lagos, Nigeria, 
while the various brands of the tablets were 
obtained from retail Pharmacies in Ibadan, Oyo 
State, Nigeria. 
 
Reagents used include glacial acetic acid, 
perchloric acid, acetic anhydride, potassium 
hydrogen phthalate, hydrochloric acid, crystal 
violet powder, methanol and chloroform. They 
were all of analytical grade. Ten different brands 
of ciprofloxacin tablets and the innovator brand 
with labelled contents of 500mg each, were 
obtained from retail pharmacies in Ibadan Oyo 
State, Nigeria.  
 
METHODS 
Thin Layer Chromatographic identification: The 
0.1%w/v pure ciprofloxacin HCl in methanol and 
equivalent solution of tablets were identified 
using thin layer chromatography (TLC) with 
ultraviolet spectroscopy detection. 
Tablet description: The colour, shape and size 
were examined by visual observation.  
Uniformity of weight determination: Twenty 
tablets from each of the ten brands was weighed 
individually using a Mettler 1180 weighing 
balance. The average weights of the tablet were 
calculated as well as their percentage deviation 
from the average weight. 
Friability Test: Twenty tablets were weighed and 
subjected to abrasion using Veego tablet 
friability tester (Model VET – 2D, India) at 25 
rev/minute. The tablets were weighed after five 
minutes and the weight compared to the initial 
weight. 
Hardness Test: This crushing strength was 
determined using a Keetan tablet hardness 
tester.  
Tablet Disintegration Test: This was determined 
at 37
o
C using Veego disintegration testing 
apparatus (model – VTDH3, Rutartek, India) until 
no particle remained on the basket of the 
system. The time taking for each of the four 
tablets tested in each of the brand was recorded. 
Dissolution rate determination (B.P. 1998)
12
: 
This was determined using the Veego 
dissolution rate testing apparatus using 0.1M 
HCl (900 ml) as the dissolution medium. The 
dissolution medium was maintained at 37 ± 
0.5
0
C and the basket was rotated at 100 r.p.m. 
Samples (10ml) were withdrawn at timed 
intervals of 10minutes for 1hour and replaced 
with 10ml fresh dissolution medium after each 
sampling. The samples were filtered and diluted 
appropriately before the absorbances were 
measured at 276 nm using ultraviolet/visible 
spectrophotometer (Perkin-Elmer model, 
Lambda 33). Six tablets were used from each 
brand.  
 
The content of ciprofloxacin HCl in each sample 
was determined based on the calibration curve 
generated at a wavelength of 276nm. The 
regression equation for the calibration curve was 
y = 713.33x  +  0.0275, r
2 
= 0.9773.  
 
The dissolution profiles of the different brands of 
ciprofloxacin HCl tablets were generated from 
the graph of the amount of ciprofloxacin HCl 
dissolved versus time. The average T70 (time for 
70% of the active drug to be dissolved) and the 
amount dissolved at 45minutes were obtained 
for each brand. 
Chemical content determination  
Ciprofloxacin HCl pure powder: - 0.1g, 0.2g and 
0.3g were dissolved in glacial acetic (15ml) acid, 
followed by the addition of freshly prepared 
mercuric (II) acetate solution (0.5ml, 1.0ml and 
1.5ml respectively) and acetic anhydride (2ml, 
4ml and 5ml respectively). The solutions were 
titrated against 0.1M acetous perchloric acid 
using 0.5%w/v crystal violet solution as indicator 
until a bluish – green end point.  
Blank titrations were carried out using 15ml 
glacial acetic acid. Titre values were adjusted by 
deducting the blank determination from the 
assay. This was carried out in triplicate. 
Ciprofloxacin HCl tablets (Innovator brand):- 
Amounts of the crushed tablet material 
equivalent to 0.1g, 0.2g, 0.3g of pure 
ciprofloxacin hydrochloride in the tablet dosage 
form of the innovator brand were weighed. 
These were dissolved in 15ml glacial acetic acid, 
followed by the addition of freshly prepared 
mercuric (II) acetate solution (0.5ml, 1.0ml and 
1.5ml respectively) and acetic anhydride (2ml, 
4ml and 5ml respectively). The solution was 
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titrated against 0.1M acetous perchloric acid 
using 0.5%w/v crystal violet solution as indicator 
until a bluish – green end point.  
Blank titrations were carried out using 15ml 
glacial acetic acid. Titre values were adjusted by 
deducting the blank determination from the 
assay. The procedure was carried out in 
triplicate. 
 
The procedure was then applied to ten other 
brands of ciprofloxacin HCl tablets sourced from 
various pharmacy outlets. 
 
RESULTS 
The TLC analysis of the pure drug and the 
various brands gave Rf values in the range of 
0.70 – 0.73 for the different brands. However, a 
particular brand (Brand J) was observed to 
contain very little amount of the active drug 
compound as the intensity of the spot was very 
weak relative to the reference pure drug and the 
other brands.  
 
The uniformity of weight determinations for all 
the brands gave values which complies with the 
official books specification for weight uniformity, 
as none of the brands deviated by up to 5% from 
the mean value (Table 1). Similarly, the friability 
results for all the brands also complied with 
official specification; all the brands gave a weight 
loss of less than the official specification of 
1%w/w (Table 2). Also the mean crushing 
strength which is an indication of the hardness of 
the tablets showed that brands A, B and C gave 
the highest crushing strength of 10.3, 12.5 and 
11.0 kg/cm
2
 (Table 1). 
 
The disintegration time obtained for nine out of 
the ten brands was less than the 15minutes 
official specification for uncoated tablets. 
However, brand J gave a disintegration time of 
21.8 ± 6.29 minutes which is far higher than the 
specification for uncoated tablets (Table 2).  
The obtained dissolution rate profile revealed 
that four of the brands i.e. E, G, I, and J did not 
attain 70% dissolution throughout the period of 
the determination. Of the remaining samples 
Brand F had the least time to achieve 70% 
dissolution. The obtained dissolution content at 
45minutes was found to be highest with brand F 
i.e. 99.82%w/v, while brand J gave the least 
value with 3.64%w/v (Table 2).  
The result of the non-aqueous titration of 
ciprofloxacin HCl pure powder at 0.1g, 0.2g and 
0.3g and the equivalent weights of the powdered 
tablets of the innovator brand is presented in 
Table 2. The values obtained with the different 
concentrations showed that the excipients did 
not affect the procedure.    
 
The application of the method to ten other 
brands showed that seven brands (A, B, C, D, E, 
F and H) had values within the range specified in 
the USP (90–110%w/v), while the remaining 




All the brands used were within their shelf life as 
at the time of the study. Ten different brands of 
ciprofloxacin hydrochloride tablets obtained from 
different retail pharmacy outlets within Ibadan 
metropolis were subjected to a number of tests 
in order to assess their biopharmaceutical and 
chemical equivalence. The assessments 
involved the use of both qualitative and 
quantitative methods of evaluation. The 
qualitative methods of evaluation includes tablet 
description i.e. colour size and shape, which 
were carried out by visual observation as well as 
thin layer chromatography (TLC), while 
quantitative evaluations used are uniformity of 
weight, friability, hardness, disintegration and 
dissolution tests as well as chemical content 
determination. 
 
The initial identification procedure using TLC 
revealed that all the brands contained 
ciprofloxacin HCl as they all gave Rf values 
ranging between 0.70 – 0.73, which compares 
well with that of the reference pure ciprofloxacin 
HCl. However the intensity of the TLC spot 
obtained for brand J was very weak relative to 
the other brands at the same concentration. This 
is an indication that the ciprofloxacin HCl content 
in brand J is far lower than the labeled content. 
The uniformity of weight determination for all the 
brands showed compliance with the official 
specifications (B.P 1998)
12
, as none of the 
brands deviated by up to 5% from their mean  
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values and no tablet deviated by twice this value 
 
Table 1: Uniformity of weight, Friability and Hardness determination of ten brands   








Uniformity of Weight 
(g) 
A 0.000 10.3 ± 0.57 0.785 ± 0.078 
B 0.000 12.5 ± 0.5 0.775 ± 0.074 
C 0.710 11 ± 0.0 0.705 ± 0.005 
D 0.510 7.0 ± 1.0 0.980 ± 0.100 
E 0.170 8.2 ± 0.76 0.785 ± 0.060 
F 0.260 8.8 ± 1.89 0.785 ± 0.007 
G 0.000 7.2 ± 2.75 0.799 ± 0.012 
H 0.290 5.3 ± 1.04 0.980 ± 0.010 
I 0.040 6.7 ± 0.29 0.786 ± 0.010 
J 0.010 8.5 ± 3.5 0.960 ± 0.012 
 
 
Table 2: Disintegration and Dissolution rate profile for ten brands of ciprofloxacin   
               hydrochloride tablets 
Dissolution Rate Profile (% Dissolution ) Sample  Disintegration Time 
(minutes) Time to attain 70% dissolution 
(T70) (Minutes) 
% Dissolution at 45 
minutes (C45) 
A 3.25  ± 0.95 41.5 72.80 
B 2.63  ± 0.48 31.0 88.27 
C 5.50  ± 1.29 43.0 71.89 
D 2.63  ± 0.48 24.0 83.72 
E 7.00  ± 1.83 - 38.22 
F 2.50  ± 0.58 14.4 99.82 
G 12.00  ± 0.82 - 30.94 
H 1.25  ± 0.5 45.5 69.16 
I 3.63  ± 1.11 - 50.96 
J 21.75  ± 6.29 - 3.64 
 
 
Table 3: Ciprofloxacin HCl content of pure and innovator brand of ciprofloxacin HCl tablet as determined by 
non-aqueous titration using acetous HClO4 as titrant and crystal violet as indicator 
 Chemical content      (%w/w) Weight of sample 
(pure powd / equiv wts of tab.) (g) Pure Ciprofloxacin powd Powdered Ciprofloxacin tab. 
(Innovator brand) 
0.1 99.12 ± 1.48 99.97 ± 2.78 
0.2 100.17 ±1.54 98.01 ± 1.89 
0.3 100.37 ± 1.03 100.27 ± 2.05 
 
 
Table 4: Ciprofloxacin HCl content of ten brands of ciprofloxacin HCl tablets as determined by non-aqueous 
titration using acetous HClO4 as titrant and crystal violet as indicator 
Brand  % Chemical content    (%w/w) Brand  % Chemical content    (%w/w) 
A 96.17 ± 1.92 F 90.39 ±  2.76 
B 90.62 ± 2.05 G 84.14 ± 1.12 
C 90.62 ± 2.04 H 90.59 ± 2.75 
D 90.03 ± 3.45 I 87.27 ± 0.70 
E 91.85 ± 3.36 J 19.72 ± 15.62 
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(Table 1). This indicates that the weights of the 
tablets in each batch within each brand are 
within the expected official specifications. 
 
Similarly, all the brands gave less than 0.8%w/w 
loss in weight with the friability test 
determination; this is less than the official 
specification of 1%w/w (B. P. 1998). This 
showed that all the brands could withstand 
abrasion without loss of tablet integrity. The 
mean crushing strength determination which is a 
measure of the degree of hardness of the tablets 
gave the highest values of 12.5, 11.0 and 
10.3kgcm
-2
 for brands B, C and A respectively, 
while the other brands had values less than 
9.0kgcm
-2
. Although, the crushing strength is not 
an official method of assessing tablet quality, it is 
still useful in assessing the integrity of tablet 
dosage forms.  
 
All the brands except brand J passed the 
disintegration test (Table 2). The B.P. 1988 
specifies 15 minutes and the inability of brand J 
to disintegrate within this time limit is an 
indication that the drug will show poor 
disintegration in the gastrointestinal tract. Hence, 
the tablet may not be broken down to facilitate 
release of content into the system. This usually 
has a direct effect on the dissolution and 
bioavailability of the drugs. 
 
The B.P. specifies that not less than 70%w/w 
labeled content should dissolved at 45minutes. 
The result obtained from this study revealed that 
four of the brands; E, G, I and J did not achieve 
this concentration at 45minutes (Table 2, Figure 
1). Similarly the four brands could not achieve 
70% dissolution throughout the 1 hour period of 
the determination. The obvious implication of this 
is that the four brands may exhibit poor 
bioavailabilty profile in vivo. Dissolution rate has 
been reported to have a direct bearing on the 
bioavailability profile of tablet dosage forms as it 
can be used to predict the drug release pattern 
in vivo
1
. Brand J with the 3.64%w/v dissolution at 
45minutes corroborates the disintegration rate 
result obtained for the brand. The disintegration 
time of 21.8 ± 6.29 minutes obtained for brand J 
may definitely indicate that the drug would not be 
released into the dissolution medium easily. 
Although comparative bioavailability studies 
would be required to draw clinical conclusions, 
the failure of some of these products to meet the 
B.P. requirements for dissolution indicates 
formulation differences that could result in 
differences in bioavailability. 
 
A study on 85 generic products from 21 
countries reported that 91% of the generic 
piroxicam products evaluated failed to meet the 
routine in vitro USP quality assurance criteria for 
potency and or dissolution
18
. This difference in 
dissolution could result in altered bioavailability 
and hence potency, which may result in 
therapeutic failure. 
 
One of the objectives of this study is to provide a 
simple easy to use, inexpensive and sensitive 
analytical technique, which could be used in the 
monitoring of the quality of ciprofloxacin HCl 
tablet available within the drug distribution 
system in a developing country. 
The chemical content determination procedure 
used in this study involves the modification of the 
non- aqueous titration with potentiometric end 
point determination specified in B.P for 
ciprofloxacin HCl pure powder. The modification 
involves the addition of acetic anhydride and 
mercuric (II) acetate solution, using 5%w/v 
crystal violet solution as indicator.  
The application of the non-aqueous titrimetric 
procedure was based on the following equation; 
 C17H18FN3O3.HCl + Hg(OAc)2 + HClO4                   
2C17H18FN3O3.H
+
  +  HgCl2  +  2CH3COOH + 
2ClO
-
4                                                                                                   
 
The pure ciprofloxacin HCl powder at 0.1, 0.2 & 
0.3g gave 99.12 ± 1.48, 100.17 ±1.54 & 
100.37±1.03%w/w respectively which is in line 
with the USP 1990 specification of 90 – 
110%w/w. Similarly, equivalent weights of the 
powdered ciprofloxacin HCl tablets (innovator 
brand) gave 99.97 ± 2.78, 98.01 ± 1.89 & 100.27 
± 2.05w/w respectively. The procedure was 
repeatable with consistent results and very good 
interday and intraday precision. The excipients 
of the tablets did not interfere with the assay 
procedure and result as the colour end point was 
clear and stable.  
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The suitability of this method for the assay of 
ciprofloxacin HCl tablets was determined by 
applying the method to ten other brands of the 
drug. Seven of the brands (A, B, C, D, E, F and 
H) gave values that conform to the U.S.P 
specification of ciprofloxacin HCl content, while 
the remaining three brands (G,I and J), gave 
lower contents (Table 3). The percentage 
deviation from the mean for all the samples at 
different concentrations was not greater than ± 
3.5%w/w, except Brand J, which deviated by ± 
15.62%w/w.  
The method was able to detect an apparently 
fake brand of ciprofloxacin HCl tablets i. e. brand 
J, which gave a percentage content of 19.72 
±15.62%w/w; thus confirming the result obtained 
from the thin layer chromatographic analysis of 
the brand, which raises questions as to the 
quality of the brand. This implies that the method 
can be successfully used to detect apparently 
fake ciprofloxacin tablets.   
 
Non-aqueous titration procedure has been 
reported for the chemical content determination 
of various drugs such as chlodiazepoxide, 
chlorpromazine, pyrimethamine, metronidazole, 
salbutamol phosphate, promethazine HCl, 
methyldopa, lignocaine, ofloxacin and 
norfloxacin
5, 12
. Earlier reports on ciprofloxacin 
HCl tablet dosage by colorimetric method gave 
101.23 ± 2.85%w/w, while microbiological assay 
gave 97.96 ± 0.87%w/w
10
. Liquid chromatoghtic 
technique is the official method specified in the 
official books for ciprofloxacin HCl tablets. 
However, the equipment is not readily affordable 
due to high cost of purchase andmaintainance. 
Hence the need to develop a simple method 
which can easily be used to monitor the quality 
of the drug products cannot be over 
emphasized. 
 
It is quite interesting to note that brand J is 
obviously a fake product based on the results 
obtained for the critical quality control 
parameters such as TLC identification, 
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Brands G and I could be regarded as 
substandard products; their failure of the 
chemical content determination is reflected in 
their dissolution rate profile in which both of them 
could not achieve 70% dissolution at 45minutes 
and none of them achieved 70% dissolution 
throughout the 1 hour period of the 
determination. 
 
Brand E with 91.85 ± 3.36%w/w chemical 
content could not achieve 70% dissolution, while 
its dissolved content at 45 minutes was 
38.22%w/v. This obviously indicates a problem 
with dissolution which may indicate formulation 
problem. Thus the fact that  a product passes 
the chemical content determination does not 
indicate that the product will be the 
therapeutically useful. 
Ironically, brands A, B and C with very high 
crushing strength still exhibited very good quality 
control parameters such as dissolution profile, 
disintegration rate and chemical content 
determination. This indicates that hardness test 
is not a critical quality control parameter. 
It was quite interesting that all the brands had 
NAFDAC registration numbers indicating that the 




The differences in quality control parameters 
observed in this study with respect to the 
ciprofloxacin HCl tablet dosage form used in the 
study have implications in terms of product 
equivalency and standards of multisourced 
products available within the study area. 
Healthcare providers should take this into 
account. 
The non- aqueous titrimetric procedure for the 
assay of ciprofloxacin HCl used in this study is 
simple, inexpensive, reproducible and easy to 
use and could be used in routine monitoring of 
the quality of ciprofloxacin HCl pure powder and 
tablets, especially in the absence of high 
technology equipment that are not easily 
available in most developing countries.  
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